ONT
NEUTRALOxford Nanopore Announces Director Share Incentive Plan
The biotechnology company has announced details of a director's participation in its employee share plan.
Oxf Nanopore Technologies
124.80GBX
-4.51%
Market Cap
1.21B
Volume
1.33M
73% of avg
P/E Ratio
-1057.27
EPS (TTM)
-0.12
Beta
0.82
Day Range
124.30p - 131.60p
52 Week Range
88.60p124.80p224.80p
124.80p
Upcoming Events
ONT
NEUTRALOxford Nanopore Provides AGM Shareholder Engagement Update
The healthcare technology company provides an update on shareholder engagement following its recent AGM, highlighting the Board's focus on long-term value creation and the appointment of a new CEO.
ONT
NEUTRALOxford Nanopore Appoints New CEO
The healthcare technology company has appointed a new CEO to lead the business into its next phase of growth.
ONT
NEUTRALOxford Nanopore to Participate in Upcoming Investor Conferences
The healthcare technology company will be presenting at several investor conferences in December.
ONT
NEUTRALOxford Nanopore Director Increases Shareholding
The Chief Financial Officer of the biotechnology company has purchased additional shares through the company's Share Incentive Plan.
ONT
NEUTRALOxford Nanopore postpones investor event, reaffirms guidance
The biotechnology company is postponing a virtual investor event as it undergoes a CEO transition, but reaffirms its full-year 2025 revenue growth guidance.
ONT
NEUTRALOxford Nanopore to Host Investor Event and Participate in Upcoming Conferences
The biotechnology company will be hosting an investor event and participating in several investor conferences in November.
ONT
NEUTRALOxford Nanopore Director Increases Shareholding
The chief financial officer of the biotechnology company has purchased additional shares through the company's share incentive plan.
ONT
NEUTRALOxford Nanopore Director Increases Shareholding
The chief financial officer of the biotechnology company has purchased additional shares through the company's share incentive plan.
ONT
GOODOxford Nanopore Reports Strong H1 Growth, Reaffirms Full Year Guidance
This molecular sensing technology company reported strong H1 revenue growth of 28% at constant currency, with broad-based expansion across all regions and customer segments. Despite ongoing losses, adjusted EBITDA improved significantly.